New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries

PAPERBACK
$43.50

Download

Table of Contents
Front Matter R1-R16
1. Summary 1-18
2. Priority Setting for Health-Related Investments: A Review of Methods 19-29
3. Overview of the Analytic Approach 30-43
4. Comparison of Disease Burdens 44-62
5. Predictions of Vaccine Development 63-75
6. Assessing the Likely Utilization of New Vaccines 76-81
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines 82-105
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 106-120
9. Findings, Conclusions, and Recommendations 121-142
Appendix A: Selection of Vaccine Candidates for Accelerated Development 143-148
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness 149-158
Appendix C: The Burden of Disease Resulting from Diarrhea 159-169
Appendix D-1: The Prospects for Immunizing Against Dengue Virus 170-177
Appendix D-2: The Prospects for Immunizing Against Escherichia coli 178-185
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b 186-196
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus 197-207
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus 208-222
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus 223-240
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae 241-250
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis 251-266
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses 267-274
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. 275-286
Appendix D-11: The Prospects for Immunizing Against Rabies Virus 287-298
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus 299-307
Appendix D-13: The Prospects for Immunizing Against Rotavirus 308-318
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi 319-328
Appendix D-15: The Prospects for Immunizing Against Shigella spp. 329-337
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A 338-356
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae 357-375
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae 376-389
Appendix D-19: The Prospects for Immunizing Against Yellow Fever 390-402
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 403-411
Appendix F: Technical Notes 412-412
Appendix G: Biographical Notes on Committee Members 413-417
Appendix H: Additional Sources of Advice to the Committee 418-419
Appendix I: Contents of Supplement to Volume II 420-420
Appendix J: Preface to Volume I 421-422
Appendix K: Contents to Volume I 423-423
Index 424-432

Table of Contents

Front Matter R1-R16

1. Summary 1-18

2. Priority Setting for Health-Related Investments: A Review of Methods 19-29

3. Overview of the Analytic Approach 30-43

4. Comparison of Disease Burdens 44-62

5. Predictions of Vaccine Development 63-75

6. Assessing the Likely Utilization of New Vaccines 76-81

7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines 82-105

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 106-120

9. Findings, Conclusions, and Recommendations 121-142

Appendix A: Selection of Vaccine Candidates for Accelerated Development 143-148

Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness 149-158

Appendix C: The Burden of Disease Resulting from Diarrhea 159-169

Appendix D-1: The Prospects for Immunizing Against Dengue Virus 170-177

Appendix D-2: The Prospects for Immunizing Against Escherichia coli 178-185

Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b 186-196

Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus 197-207

Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus 208-222

Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus 223-240

Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae 241-250

Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis 251-266

Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses 267-274

Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. 275-286

Appendix D-11: The Prospects for Immunizing Against Rabies Virus 287-298

Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus 299-307

Appendix D-13: The Prospects for Immunizing Against Rotavirus 308-318

Appendix D-14: The Prospects for Immunizing Against Salmonella typhi 319-328

Appendix D-15: The Prospects for Immunizing Against Shigella spp. 329-337

Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A 338-356

Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae 357-375

Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae 376-389

Appendix D-19: The Prospects for Immunizing Against Yellow Fever 390-402

Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 403-411

Appendix F: Technical Notes 412-412

Appendix G: Biographical Notes on Committee Members 413-417

Appendix H: Additional Sources of Advice to the Committee 418-419

Appendix I: Contents of Supplement to Volume II 420-420

Appendix J: Preface to Volume I 421-422

Appendix K: Contents to Volume I 423-423

Index 424-432

Attachment 3 Age Related Mortality “Trade-Offs”